Search in the Abstract Database

Abstracts Search 2019

P432 Barriers to prescribing anti-TNF therapy in inflammatory bowel disease (IBD) across newly industrialised emerging market countries: an analysis of the ‘EXPLORE’ study

B. D. Ye*1, J. K. Yamamoto Furusho2, M. Rana Qasim Khan3, O. Fadeeva3, D. Demuth4, J. Qian5, I. L. Khalif6, T. Chia-Hung7, M. Toruner8, A. H. Othman9, W. Chan10, E. Ponce de Leon11, M. Guennec12, C. Sison13, E. Uberti Foppa14, A. Armuzzi15

1University of Ulsan College of Medicine, Asan Medical Center, Department of Gastroenterology and Inflammatory Bowel Disease Center, Seoul, South Korea, 2National Institute of Medical Sciences and Nutrition, Department of Gastroenterolgy, Mexico city, Mexico, 3Takeda Pharmaceutical International AG Singapore branch, Singapore, Singapore, 4Takeda International - UK Branch, London, UK, 5Peking Union Medical College Hospital, Beijing, China, 6Federal State Budgetary Institution ‘State Scientific Center of Coloproctology n.a. A.N. Rizhikh’ of the Ministry of Public Health of Russian Federation, Inflammatory and Functional Bowel Diseases Research Unit, Moscow, Russian Federation, 7National Taiwan University, Taipei, Taiwan, 8Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey, 9King Khalid University Hospital , King Saud University, Department of Medicine, Riyadh, Saudi Arabia, 10Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 11Fundación CardioInfantil, Instituto de Cardiología, Bogota, Colombia, 12IQVIA, Saint Ouen, France, 13IQVIA, Makati City, Philippines, 14PRA Health Sciences, Global Medical Affairs – Research, Europe Development Centre, Takeda International – UK Branch, London, UK, 15Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy

Background

Physician challenges to prescribing anti-tumour necrosis factor (TNF) therapy among patients with ulcerative colitis (UC) and Crohn’s disease (CD) in real-world clinical practice remains limited in the newly industrialised countries in APAC, Latin America (LatAm), and Russia, Middle East (RME) regions. We aimed to assess physician-perceived barriers to prescribing anti-TNF therapy in local settings.

Methods

The EXPLORE study is a chart review of IBD patients describing indicators and predictors of suboptimal response to anti-TNF therapy. It comprises a cross-sectional survey (completed during June 2017 till June 2018) of IBD specialists to identify local barriers to prescribing anti-TNF in real clinical practice, including those perceived to be faced by non- IBD GI specialists managing IBD patients.

Results

The survey was completed by 73 IBD specialists. In 2016, the median (min–max) number of biologic-naïve UC and CD patients referred to IBD specialist sites was 30 (1–811) and 40 (2–1000), respectively. Amongst IBD patients eligible for anti-TNF therapy who did not receive it, estimates were higher for CD (median [min–max]: 30% [0–100%]) compared with UC (20% [0–100%]). Among IBD specialists, ‘patient affordability’ (51%), ‘patient fear of side effects’ (47%), and the ‘complex reimbursement process’ (33%) were the three most frequent barriers to prescribing anti-TNF therapy. For non-IBD GI specialists, ‘physician lack of experience with anti-TNF therapy’ (48%), ‘patient affordability’ (47%), and ‘patient fear of side effects’ (45%) and ‘perceived safety risk’ (45%) were the three most common perceived barriers. Regional differences are shown in Table 1.

Table 1. The most common barriers to prescribing anti-TNF therapy by IBD specialists and non-IBD gastrointestinal (GI) specialists in the newly industrialised countries in Asia Pacific (APAC), Latin America (LatAm), and Russia, Middle East (RME) regions.

Hospitals were the most common setting to administer anti-TNF therapy for 78%, 67%, and 46% of patients in APAC, RME, and LatAm, respectively; however, ‘lack of staff in infusion centres’ (36%) and ‘low numbers of infusion centres’ (32%) were frequently reported challenges.

Conclusion

EXPLORE is one of the first IBD studies of its kind conducted in the newly industrialised countries. The conducted physician’s survey within this study identified key barriers to prescribing anti-TNF therapy. This analysis highlighted an unmet medical need, where a large proportion of IBD patients eligible for biologic therapy did not receive it. Better biologic reimbursement coverage, physician education strategies, along with availability of safer biologic therapies and greater infusion capacity, may be required in these countries to improve IBD patient management.